CULLINAN THERAPEUTICS, INC. Operating Lease, Expense
CULLINAN THERAPEUTICS, INC. (CGEM) reported Operating Lease, Expense of $300.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-06-30 was $300.00K, a 0.00% change year-over-year.
- CULLINAN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2026-03-31 was $300.00K, a 0.00% change year-over-year.
- CULLINAN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-12-31 was $300.00K, a 0.00% change year-over-year.
- CULLINAN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2025-09-30 was $300.00K, a 0.00% change year-over-year.
- CULLINAN THERAPEUTICS, INC. operating lease, expense for fiscal 2025 was $1.20M, a 0.00% change from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. operating lease, expense for fiscal 2024 was $1.20M, a 29.41% decline from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. operating lease, expense for fiscal 2023 was $1.70M, a 54.55% increase from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $1.10M, a 83.33% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $300.00K 10-Q · filed 2026-08-06 | $600.00K 10-Q · filed 2026-08-06 | $900.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $300.00K 10-Q · filed 2026-05-07 | $600.00K derived: sum of 2 quarters · filed 2026-05-07 | $900.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $600.00K derived: sum of 2 quarters · filed 2026-03-10 | $900.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.20M 10-K · filed 2026-03-10 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-06 | $600.00K derived: sum of 2 quarters · filed 2026-08-06 | $900.00K 10-Q · filed 2025-11-06 | $1.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-06 | $600.00K 10-Q · filed 2026-08-06 | $900.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $300.00K 10-Q · filed 2025-05-08 | $600.00K derived: sum of 2 quarters · filed 2026-03-10 | $900.00K derived: sum of 3 quarters · filed 2026-03-10 | $1.20M derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $600.00K derived: sum of 2 quarters · filed 2026-03-10 | $900.00K derived: sum of 3 quarters · filed 2026-03-10 | $1.20M 10-K · filed 2026-03-10 |
| 2024-09-30 | $300.00K 10-Q · filed 2025-11-06 | $600.00K derived: sum of 2 quarters · filed 2025-11-06 | $900.00K 10-Q · filed 2025-11-06 | $1.30M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-07 | $600.00K 10-Q · filed 2025-08-07 | $1.00M derived: sum of 3 quarters · filed 2025-08-07 | $1.40M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-08 | $700.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.10M derived: sum of 3 quarters · filed 2025-05-08 | $1.50M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $800.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.20M derived: sum of 3 quarters · filed 2025-02-27 | $1.70M 10-K · filed 2025-02-27 |
| 2023-09-30 | $400.00K 10-Q · filed 2024-11-07 | $800.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.30M 10-Q · filed 2024-11-07 | $1.70M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-08 | $900.00K 10-Q · filed 2024-08-08 | $1.30M derived: sum of 3 quarters · filed 2024-08-08 | $1.60M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $400.00K 10-Q · filed 2024-05-15 | $900.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.20M derived: sum of 3 quarters · filed 2024-05-15 | $1.30M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $800.00K derived: sum of 2 quarters · filed 2024-03-14 | $900.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.10M 10-K · filed 2024-03-14 |
| 2022-09-30 | $300.00K 10-Q · filed 2023-11-08 | $400.00K derived: sum of 2 quarters · filed 2023-11-08 | $600.00K 10-Q · filed 2023-11-08 | $600.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $100.00K 10-Q · filed 2022-08-10 | $300.00K 10-Q · filed 2023-08-10 | $300.00K derived: sum of 3 quarters · filed 2023-08-10 | $500.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $100.00K 10-Q · filed 2023-08-10 | $200.00K derived: sum of 2 quarters · filed 2023-08-10 | $400.00K derived: sum of 3 quarters · filed 2023-08-10 | $600.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $300.00K derived: sum of 2 quarters · filed 2023-03-09 | $500.00K derived: sum of 3 quarters · filed 2023-03-09 | $600.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $200.00K 10-Q · filed 2021-11-09 | $400.00K derived: sum of 2 quarters · filed 2021-11-09 | $500.00K 10-Q · filed 2021-11-09 | $800.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-06-30 | $200.00K 10-Q · filed 2021-08-10 | $300.00K 10-Q · filed 2021-08-10 | $600.00K derived: sum of 3 quarters · filed 2022-03-17 | $800.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2021-03-31 | $200.00K 10-Q · filed 2021-05-14 | $400.00K derived: sum of 2 quarters · filed 2022-03-17 | $600.00K derived: sum of 3 quarters · filed 2022-03-17 | $800.00K derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $400.00K derived: sum of 2 quarters · filed 2022-03-17 | $600.00K derived: sum of 3 quarters · filed 2022-03-17 | $600.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $200.00K 10-Q · filed 2021-11-09 | $400.00K derived: sum of 2 quarters · filed 2021-11-09 | $400.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $200.00K 10-Q · filed 2021-08-10 | $300.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |